MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib

he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients

Proxygen and Merck collaborates to develop molecular glue degraders

The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.

Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital

The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.

Ovensa and Celanese to collaborate to advance precision drug delivery

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved

LintonPharm to release data on Catumaxomab at ASCO meeting

The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis

Next-gen immunotherapy drug shows promise in several advanced-stage cancers

Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells

New data demonstrate clinical benefit of Roche’s glofitamab

Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma

Borrena approval strengthens Pfizer position in China NSCLC market: GlobalData

According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029

European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer

This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC